Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TomorrowLAND primary PCI strategy in STEMI
jRCTs042250026Recruiting
- Sponsor
- Kaneka
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of nicorandil in myocardial infarction (MI) (2 arms), sponsored by Kaneka. Primary endpoint: Incidence rate of slow flow or no-reflow during primary PCI. Started May 2025; status: recruiting.
02
Drugs
nicorandil
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on jRCTs042250026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs042250026.